Aperio Group’s Cogent Biosciences COGT Stock Holding History

Aperio Group’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-193	Closed	-$2K	–	2404
2019 Q2	$2K	Buy	+193	New	+$2.57K	﹤0.01%	2925

Other funds holding COGT

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aperio Group's COGT Position: Q3 2019 in Review

Aperio Group sold out of Cogent Biosciences (COGT) in Q3 2019, closing a stake of 193 shares — an estimated $2K sold.

Aperio Group first reported a position in COGT in Q2 2019 and held it in 1 quarter. The position peaked at $2K in Q2 2019. 36 funds tracked by Wall St. Rank hold COGT as of Q3 2019.

Aperio Group reported no remaining Cogent Biosciences position as of Q3 2019 after selling out during the quarter.
Aperio Group sold 193 Cogent Biosciences shares in Q3 2019, an estimated $2K.
Aperio Group first reported a position in Cogent Biosciences in Q2 2019 and held it in 1 quarter.
Aperio Group's Cogent Biosciences position peaked at $2K in Q2 2019.
36 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.